No Data
Guangdong Wannianqing: Report for the third quarter of 2024
Guangdong Wannianqing: Summary of the 2024 Semi-Annual Report
Guangdong Wannianqing: Semi-Annual Report 2024
Jiangxi Wannianqing Cement (301111.SZ): The net income in the first half of the year was 15.1038 million yuan, a year-on-year decrease of 39.11%.
Jiangxi Wannianqing Cement (301111.SZ) announced its semi-annual report for 2024, with a total operating income of 0.152 billion yuan, an increase of 3.77% compared to the same period last year. The net income attributable to shareholders of the listed company was 15.1038 million yuan, a decrease of 39.11% compared to the same period last year. The net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 8.5578 million yuan, a decrease of 49.52% compared to the same period last year. The basic earnings per share were 0.0944 yuan.
Express News | Jiangxi Wannianqing Cement: Net income in the first half of 2024 decreased by 39.11%.
Jiangxi Wannianqing Cement (301111.SZ): Currently no involvement in traditional Chinese medicine planting business.
Jiangxi Wannianqing Cement (301111.SZ) stated on the investor interaction platform on July 11 that the company has no current involvement in the planting industry of traditional Chinese medicine. The company focuses on the research and development, production and sales of Chinese patent medicine, and has a close relationship with upstream traditional Chinese medicine materials. The fluctuation of traditional Chinese medicine material prices has a certain degree of impact on the company's production costs, while the company's product prices are considered comprehensively based on objective environment, market demand, and product costs, so the impact of traditional Chinese medicine material price increases on the company's performance cannot be generalized.
No Data
No Data